Navigation Links
DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
Date:10/1/2008

Ticker Symbol: CUR

QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Mr. John Schafer, President and CEO of the Company, will be presenting a company overview at the Third Annual JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 1:30 PM (ET). This conference is taking place in New York (New York) on October 6 and 7, 2008.

The event will be webcast live through DiagnoCure's website at http://www.diagnocure.com, through a link on the Investors page - Presentations and Conferences. An archived presentation will be available on the Web site for 90 days.

More information on the Third Annual JMP Securities Healthcare Focus Conference can be found at http://www.jmpsecurities.com.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit http://www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.


'/>"/>
SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
2. DiagnoCure to host Q2 2008 earnings conference call and webcast
3. DiagnoCure announces second quarter 2008 results
4. DiagnoCures GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
5. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem cells ... due to its potential for revolutionizing human disease treatment. There are multiple HSC ... stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... one-stop portal for all the knowledge resources, including white papers, guides, handbooks, case ... more. , To access more than 9,000 documents, webinars and videos available ...
(Date:12/6/2016)... , ... December 06, 2016 , ... 'Tis the season ... daily routines. That means it's also the season when eating healthy, staying active, and ... diabetes) on schedule is harder to do. , "Shopping trips, parties and family ...
(Date:12/6/2016)... ... 06, 2016 , ... Specialty Technical Publishers (STP) and Specialty ... Consortium (IAPC) EHS audit protocol for Great Britain . Leading companies around ... EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 According to a new report ... by Application - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", the ... to reach $5,255 million by 2022, growing at a CAGR of 6.4% from ... than four-fifths share. Continue Reading ... ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)... Dec. 5, 2016   TrainerMD , the first HIPAA compliant ... new collaboration with Styku . Styku, a ... Kinect hardware to provide users world-class, real-time 3D body scanning and ... the means to see, hear and feel their health like never ... , , ...
Breaking Medicine Technology: